BioNTech is a biotechnology company based in Germany that specializes in the development of immunotherapies and personalized medicine, particularly in the field of cancer treatment. Established in 2008, the company gained widespread recognition for its role in developing one of the first mRNA-based vaccines for COVID-19, in partnership with Pfizer. BioNTech focuses on harnessing the body’s immune system to fight diseases, utilizing advanced technologies like messenger RNA (mRNA) to create targeted therapies. Its innovative approach aims to provide more effective treatment options for various illnesses, including infectious diseases and cancer.
BioNTech transitions from COVID-19 vaccine success to focus on mRNA-based cancer therapies. Despite a decrease in profits, BioNTech's revenues outperformed market expectations in late 2024. Strategic focus on BNT327, a…